Abstract

STUDY ON LOW-DOSE WEEKLY CISPLATIN INDUCED ACUTE TOXICITIES WITH CONCURRENT CHEMORADIATION THERAPY IN HEAD & NECK AND CERVICAL CANCER

Anitha A., Prudence A. Rodrigues*, Madhulika Vijayakumar and Aadharshini G.

.

Abstract

Introduction: This study investigates acute toxicities caused by weekly cisplatin in head and neck, and cervical cancer patients. It examines the prevalence rate and risk factors of toxicities, categorizing them to improve understanding and management. Objectives: The objective of the present research was to ascertain the frequency rate of acute toxicities induced by weekly cisplatin with concurrent chemoradiation and to categorize the acute toxicities. We also identified the risk factors associated with weekly cisplatin induced acute toxicities. Materials and Methods: This prospective observational study investigated the adverse effects of weekly cisplatin with concurrent chemoradiation therapy in 70 patients. The study found that 75.71% developed anemia, followed by leukopenia, neutropenia, and thrombocytopenia. Other adverse effects included dysphagia, alopecia, weight loss, vomiting, diarrhea, constipation, and nephrotoxicity. Results: The majority of patients (75.71%) developed anemia, followed by leukopenia (48.51%), neutropenia (37.14%), and thrombocytopenia (27.14%). Most adverse effects were Grade 1, with a few Grade 3 events. A significant association was found between anemia and diagnosis. Conclusion: This study emphasizes the importance of monitoring hematological parameters in patients undergoing cisplatin-based chemotherapy to detect and manage adverse effects, improving patient outcomes and minimizing complications. Regular blood count monitoring and patient education are crucial.

Keywords: Cisplatin, head and neck cancer, cervical cancer, CTCAE, acute toxicities, prevalence rate, risk factors.